IL18 and acute kidney injury: In the present study, high‐dose intraperitoneal cDDP administration significantly increased plasma levels of IL‐18 and GGT alongside renal biomarkers like BUN, CR, UA, and decreased levels of total plasma proteins and albumin, indicating the onset of AKI.